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Modifications in the timing and dosage of immuno-
suppression can ameliorate the morbidity and mor-
tality that has prevented widespread use of intestinal 
transplantation (ITxl in children. Thirty-six patients re-
ceiving ITx, aged 5 months to 20 years were given 
2-3 mg(kg of rabbit anti-thymocyte globulin (rATG, 
thymoglobulin@1 just before ITx, and 2-3 mg(kg post-
operatively (total 5 mg(kgl. Twice daily doses of 
tacrolimus (TACI were begun enterally within 24 h af-
ter graft reperfusion with reduction of dose quantity or 
frequency after 3 months. Prednisone or other agents 
were given to treat breakthrough rejection. After 8-
28 months follow-up (mean 15.8 ± 5.31, 1- and 2-year 
patient and graft survival is 100% and 94%, respec-
tively. Despite a 44% incidence of acute rejection in 
the first month, 16 of the 34 (47%1 survivors are on 
TAC (n = 141 or sirolimus (n = 21 monotherapy; 15 re-
ceive TAC plus low dose prednisone; one each receive 
TAC plus sirolimus, TAC plus azathioprine and TAC plus 
sirolimus and prednisone. There was a low incidence of 
immunosuppression-related complications. This strat-
egy of immunosuppression minimized maintenance 
TAC exposure, facilitated the long-term control of re-
jection, decreased the incidence of opportunistic infec-
tions, and resulted in a high rate of patient and graft 
survival. 
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Introduction 
Intestinal transplantation (ITx) has become the standard of 
care for children with intestinal failure who have complica-
tions of total parenteral nutrition (TPN) (1-3). As with other 
whole organs, short- and long-term survival is dependent 
on surgical technique, preservation technology and ade-
quate immunosuppressive therapy. The immunosuppres-
sion must be sufficient to allow early graft survival. Yet, 
ultimate outcomes depend on the extent to which main-
tenance drug therapy is needed. Too much' long-term im-
munosuppression is associated with drug toxicity, infec-
tions and tumors (4). 
The cornerstone of immunosuppression for ITx has been 
TAe plus prednisone (1-4). In an effort to eliminate re-
jection, short cour~es of 'third' agents have been added 
in many centers (e.g. cyclophosphamide, anti-lymphocyte 
globulin (ALG), and more recently, daclizumab) and(or long-
term maintenance has been augmented with azathioprine 
(AZA), mycophenolate mofetil (MMF) or sirolimus (SIR) 
(1). Although some of these protocols have yielded a very 
low incidence of rejection and marginally higher early pa-
tient and graft survival, they have been difficult to evalu-
ate because of limited case numbers and short follow-up. 
Because of an unacceptable rate of early and late mortality 
and morbidity from drug toxicity per se, or from the well-
known complications of global immune depression (e.g. 
infections and malignant tumors) (1,4), the 1- and 2-year 
survival of pediatric recipients of intestine has been 54% 
and 40% in registry compilations (International Intestinal 
Transplant Registry, May 31, 2003) (5) 
It has been suggested that the conventional use of mul-
tiagent prophylactic immunosuppression could have the 
self-defeating effect of interdicting natural tolerogenic 
mechanisms, there:by making the patient permanently de-
pendent on heavy maintenance treatment (6). To avoid this 
self-defeating effect of immunosuppression, two modifi-
cations in policy were instituted (7). First, rATG was ad-
ministered peri-operatively instead of the usual practice of 
giving a course of 5-10 smaller daily postoperative doses. 
Our objective was to reduce global T cell immunity be-
fore exposure to donor antigen, and to thereby bring the 
Table 1: Indications for intestinal transplantation 
Short gut syndrome21 patients (58%) 
Volvulus 
I ntestinal atresia 
Gastroschisis 
Dysmotility disorders 10 patients (27%) 
Pseudoobstruction 
Hirschsprung's 
Hypoperistalsls syndrome 
Intestinal mucosal dysfunction 2 patients (6%) 
Microvillus inclusion disease 
Previous ITx failure 2 patients (6%) 
Budd Chiari disease 1 patient (3 %) 
11 
5 
5 
6 
3 
2 
2 
anticipated donor-specific response into a more readily con-
trollable range (6,7), The lymphoid depletion also made it 
practical to give much less post-transplant immunosup-
pression than before. The results with this strategy for ITx 
have been encouraging. 
Material and Methods 
Patient population 
AI136 intestinal recipients at our center between March 2002 and November 
2003 were included. The mean age at transplantation was 7.2 ± 6.5 years 
(range O. 5-20 years); 61 % were male and 39% were female. The indications 
for ITx are listed in Table 1. Two (6%) of the 36 patients had a previous 
failed ITx. One of these failures was due to chronic rejection 6 years after a 
primary ITx alone. In the other, a multlvisceral graft had been transplanted 
in a 17-year-old boy. At the age of 20, the graft was lost when an aortic 
conduit graft aneurysm was found to be unresectable, necessitating urgent 
retransplantation. 
Patients requiring intestine-only transplantation were all UNOS (United Net-
work for Organ Sharing) status I. The 18 patients whose allografts included a 
liver as well as the intestine had a mean PELD (pediatriC end-stage liver dis-
easel score at transplant of 23; 13 of the 18 were status I due to uncontrol-
lable gastrointestinal bleeding. The allografts consisted of: small intestine 
only (n = 16), combined liver/intestine/pancreas (n = 12), all intraabdominal 
organs except colon and spleen (multivisceral, n = 6)' the entire gastroin-
testinal tract without the liver (modified multivisceral, n = 1) and intestine 
and pancreas (n = 1). All donors were cadaveric, ABO identical and se-
lected without regard for HLA match. Five patients (14%) had a positive 
cross-match. No ex vivo irradiation or other alteration of the donor organs 
was done: e.g. they were not irradiated or subjected to lymphoid deple-
tion. Seven recipients (19%) received donor bone marrow augmentation 
(8). There was no selection based on CMV status of donor or recipient 
(there were seven CMV negative reCipients who received a CMV-positive 
allograft). 
Immunosuppression 
rATG: All patients received a total of 5 mg/kg of rabbit anti-thymocyte 
Globulin IrATG, Thymoglobulin@1. The potency and other characteristics of 
this broadly reacting polyclonal preparation are similarto other antilymphoid 
globulins (ALGs) that were first used clinically in 1966 (9). However, the 
T cell specificity IS higher, and lot-to-Iot reproducibility of the currently avail-
able rATG IThymoglobulin@) has been greatly improved and used in steroid-
sparing regimens (10-13) The half-life of the circulating thymoglobulin IS 
approximately 7 days (14). Recovery of the depleted lineages beginS in 1-2 
weeks after a divided infusion of 5 mg/kg. 
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In adults, the infusion of 5 mg/kg rATG can be given over 4-6 h and can 
be completed before organ repertusion. Because oi concern that this rate 
of infusion would be too fast in children, the 5 mg/kg was routinely split 
into pre- and post-transplant doses. The first dose of 2-3 mg/kg was in-
fused intravenously over 6-8 h before allograft reperfusion. Intravenous 
dexamethasone (0.4 mg/kg) was given as pre-medication for prophylaxis 
against pOSSible cytoklne release syndrome. As soon as the operation was 
completed and the patient was moved to the intenSive care area, whatever 
remained of the 5 mg/kg (2-3 mg/kg) was infused over 6-8 h under a second 
umbrella of dexamethasone. 
TAC: Afterthe first postoperative day, maintenance monotherapy immuno-
suppression with TAC was begun enterally at a dose of 0.1 mg/kg every 
12 h. Twelve-hour TAC trough levels of 10-15 ng/mL usually were achieved 
by about 3 days. The 12-h target trough blood level of 10-15 ng/mL was 
maintained for 3 months post-transplant, after which levels of 5-10 ng/mL 
were sought. The use of sirolimus or azathioprine was considered for pa-
tients with TAC-related complications. 
For patients who were stable on twice daily oral dosing of TAC with no 
recent episodes of rejec;tion, a 'minimization' strategy was implemented at 
three post-transplant months, with the oblective of reducing TAC mainte-
nance doses from two to one dose per day, or potentially to every other 
day. Overall management Involved three steps. 
Step 1 required that the patients were well enough to reliably ingest twice 
daily oral doses of 0.1 mg/kg. Throughout the first 3 months, doses were 
adjusted to achieve TAC levels of 10-15 ng/mL. No attempt was made to 
alter the dose timing until at least 3 months, or longer if the patients were 
not yet stable at 3 months. In step 2, patients who were stable on twice 
daily TAC dosing were changed to once daily oral doses. This was done 
by incorporating the twice daily doses into a single dose. For example, a 
patient who previously was receiving 2 mg TAC in the morning and evening 
would be given 4 mg as a single oral daily dose. Subsequent amounts 
were adjusted to achieve 24-h trough TAC levels of 5-10 ng/mL. Patients 
were followed carefully with appropriate laboratory parameters and clinical 
assessment every 2 weeks. 
In step 3, a patient who was stable after 2 months on once per day dOSing 
was conSidered to be a candidate for every other day treatment. For ex-
ample, if the patient was receiving 2 mg once a day, the regimen change 
would be to 2 mg every other day. Patents were followed carefully With 
appropriate laboratory cndclinical parameters monitored every 2 weeks. 
There is no minimum TAC level for this stage, since they will vary and are 
generally non-detectable. 
Infection prophylaxis 
Intravenous ganciclovir was used In all patients for 2 weeks after transplan-
tation for CMV prophylaxis. EBV viral load and pp65 CMV antigenemia mon-
itoring (15) were routinely performed for alllTx recipients. This consisted of 
testing every 2 weeks during the first 3 months, monthly for 3 months, every 
2-3 months for another 6 months and every 3-4 months thereafter. In the 
event of increases in EBV viral load, or of CMV antigenemia, modifications of 
immunosuppression and the use of ganclclovir(hyperimmunoglobulin was 
considered (15,16). 
Diagnosis of rejection 
In all patients, allograft ileoscopy and biopsy were performed tWice a week 
for the first 2 weeks, once a week for the next 2 weeks and then once a 
month for 2 months. After the third post-transplant month, intestinal ailo-
graft biopSies were obtained according to clinical indication. All episodes of 
acute cellular rejection (ACR) were graded as mild, moderate or severe (171. 
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Mild ACR was treated with a 6-day course of dexamethasone beginning 
with an Infusion of 2 mg/kg dexamethasone on the first day. On the second 
day. 1 mg/kg was given, and on days 3-6, the doses were reduced to 0.8, 
0.6, 0.4 and 0.2 mg/kg. As soon as steroidtherapy could be provided orally, 
further treatment was with enteral prednisone. Steroid-resistant rejection 
or more severe episodes of first time rejection (such as moderate to se-
vere histologic rejection, however, with evidence of significant ulceration 
at endoscopy) were treated With anti-lymphocyte antibody therapy (OKT3 
or rATG). In addition, close monitoring of TAC levels was done in all cases 
of ACR to assure that trough levels of :': 15 ng/dL were achieved until the 
episode was resolved. 
Diagnosis of graft versus host disease (GVHDJ 
With clinical suspicion of GVHD, an attempt was made to confirm the diag-
nosis With skin biopsy or other means including a search with flow cytom-
eHY for donor leukocyte macrochimerism in peripheral blood. 
Determination of chimerism 
In cases of a sex mismatch between donor and recipient, donor cells in 
the blood or tissues were identified by fluorescence in-situ hybridization 
(FISH) for X and Y chromosomes. Otherwise, immunostaining for donor 
HLA markers was done when possible, or as the percentage of recipient 
HLA-negative cells when appropriate antibodies for donor HLA were not 
available (18,19). 
Statistical analysis 
Actuarial patient and graft survival was determined with Kaplan-Meier 
methodology. Data are expressed as mean ± SO unless otherwise 
specified. 
Results 
Patient and graft survival 
With a mean follow-up of 15.8 ± 5.3 months (median 15.7; 
range 8-28), the actuarial patient and graft survival (Kaplan 
Meier) is 100% for the first year and 94% for the second 
year (Figure 1). The attempt to augment chimerism with 
adjunct bone marrow cells (20) in 7 (19%) of the 36 recipi-
ents had no identifiable influence on outcome. 
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Figure 1: Pediatric patient and graft survival under rATG im-
munosuppresion. 
1432 
One patient died with an anatomically(histologically nor-
mal and functioning graft 16 months after multivisceral 
transplant from catheter sepsis. The other death was 
from a post-transplant Iymphoproliferative disorder (PTLD) 
17 months after multivisceral transplantation. 
Morbidity 
The array of complications of ITx and the management of 
these problems in our early experience (2,4) and more re-
cently (1) have been reported elsewhere. In a current ex-
ample of a non-transplant complication, one of the patients 
with preexisting achalasia suffered a perforated esopha-
gus during a laparoscopic procedure 8 months after trans-
plantation. The injury required repair through open tho-
racotomy. A subsequent stricture is being treated with 
esophageal dilatation. Such non-transplant complications 
may require return to TPN for variable periods. 
Renal function: Two of our 34 surviving recipients de-
veloped renal failure after 12 and 24 months from mul-
tifactorial causes that included years of intermittent sep-
sis and antibiotic treatment while on hyperalimentation; 
however, tacrolimus nephrotoxicity was assumed to be 
additive. These two patients are awaiting a kidney trans-
plant. The mean creatinine level in the other 32 survivors 
is 0.62 ± 0.35 mg/dL. Four (12.5%) of these patients are 
being treated with a single hypertensive agent. 
Pancreatic endocrine function: None of the patients de-
veloped diabetes mellitus. 
Neurotoxicity: The incidence of neuropathic side effects 
has been zero. 
Infections: There were 22 patients presenting positive 
blood cultures after transplantation: bacterial only (n = 15)' 
bacterial and fungal (yeast organisms only) (n = 7). There 
were no cases of invasive fungal infection (soft tissue dis-
ease). Fifteen asymptomatic patients had positive blood 
tests for EBV (detected by PCR; n = 12) or CMV (detected 
by pp65 antigenemia; n = 3). These patients were treated 
preemptively (16). Clinical disease developed in only one 
of these patients, The exception was a recipient of a mul-
tivisceral allograft (CMV-positive donor and recipient) who 
developed CMV enteritis, which was controlled with gan-
ciclovir. The patient subsequently died from a widely dis-
seminated PTLD. 
Intestinal grah function 
Thirty-four patients (94% of recipients) are independent 
of TPN; two (6%) of the 34 currently obtain 50% of their 
nutritional support by infusion at 10 and 20 months post-
transplant, respectively. These two patients are not yet 
considered to be treatment failures, first, because the 
grafted intestine appears histopathologically normal, and 
second, because we have had other examples of patients 
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Table 2: Patients presenting confirmed GVHD 
Flow cytometry Flow cytometry 
Donor Donor Site of Presentation Grade at symptoms" follow-up'* 
Pt# Type ITx Sex sex BM GVHD (Post-IT x days) GVHD* (Post-ITx days) (Post-ITx days) 
L/SB/P M M N Skin 24 16.1 (21) 2.5 (62) 
2 L/SB/P M M N Skin 23 I 14.1 (20) 6.7 (64) 
3 S8 F M N Skin 60 II 0.9 (27) 3.5 (47)/15 (61) 
4 S8 M F N Skin 30 I 6.8 (52) ND 
*Histologic classification at skin changes in GVHD (Grade I-IV) . 
.. Percentage of donor derived cells in peripheral blood of recipient in one or two separate measurements. 
ND = not done. 
Table 3: Patients presenting with GVHR 
Flow cytometry' Flow cytometry* 
Donor Donor Presentation at symptoms at follow-up 
Pt# Type ITx Sex sex BM (Post-ITx days) (Post-ITx days) (Post-ITx days) 
1 S8 M F N 32 6.3 (14) 0.0 (36) 
2 S8 M M N 72 ,16.1 (13) 1.0 (22)/0.0 (356) 
3 MV M F N 13 2.6 (13) 0.0 (300) 
4 MV M M N 9 2.6 (9) NO 
5 S8 M M N 10 2 (26) NO 
6 MV F F N 9 20.6 (27) 35.9 (35)/271 (235) 
• Percentage of donor derived cells in peripheral blood of these patients. ND = not done. 
These patients did not meet criteria for a diagnosis of GVHD. 
with extremely delayed graft function who subsequently 
recovered. 
Ten of the 34 (29%) surviving patients are free of all fluid, 
electrolyte and nutritional support: i.e. they have no need 
for venous access. Another 22 (65%) receive no TPN, but 
require daily or every other day calorie-free infusions, ei-
ther because of poor electrolyte absorption, or because of 
high enteric output. Most of these 22 patients still have 
ileostomies that either have not been closed, or cannot 
ever be closed (e.g. patients with Hirschsprung's disease). 
Rejection rate (30 days) 
Within the first 30 days after ITx, 16 (44%) of the 36 pa-
tients experienced ACR which was mild in seven, mod-
erate in eight and severe in one. The episodes occurred 
between 6 and 22 days (median 14), 
Out of 18 patients who received a composite graft which 
included the liver, six patients presented with ACR of the 
intestinal component of the allograft; among these six re-
jectors of the intestinal allograft, two patients also pre-
sented simultaneous ACR of the liver component of the 
allograft (11 %). None of these 18 recipients of a compos-
ite graft had an isolated liver ACR. Eleven (69%) of the 
rejections responded to intravenous administration of dex-
amethasone, while the other five (31 %) required a 5-day 
course of muromonab-CD3 (OKT3). Of the patients requir-
ing OKT3, three patients had gross and histologic evidence 
signi"ficant enough to require primary therapy with OKT3, 
and two patients received it after a course of intravenous 
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steroids. Of the 18 patients with combined transplants, 
six experienced acute rejection of the intestinal graft. This 
was not statistically different from the 10 of 18 patients 
with acute rejection in the isolated intestinal grafts. 
Rejection (after 30 days) 
At 31-90 days intestinal rejection occurred in seven pa-
tients (three recurrent and four de novo), thus resulting 
in an overall rejection incidence of 55% at 90 days post-
transplant. There were eight patients (three recurrent and 
five de novo) who presented rejection after 90 days. All but 
one episode was l"'(1ild, These late r~jections were treated in 
the same way as those occurring in the first month (see be-
low under 'Immunosuppression Dosing'). There has been 
no histopathologic or clinical evidence to date of chronic 
i ntesti na I rejection. 
Graft versus host disease 
Histologically-proven GVHD, manifesting primarily as der-
matitis, was seen in four patients (11 %) 1-2 months after 
transplantation (Table 2). Six additional patients (17 %), who 
had peripheral blood donor chimerism measurable with 
flow cytometry, presented after 9 days to 2.5 months 
with non-specific signs and symptoms that included fever, 
arthralgias and skin reactions. Although skin biopsies did 
not permit an unqualified diagnosis of GVHD, their symp-
toms prompted testing for peripheral blood cell chimerism. 
The syndrome was attributed to graft versus host reactions 
(GVHR) (Table 3). None of the 10 patients had been given an 
adjunct bone marrow cell infusion. Asymptomatic patients 
were not tested for chimerism. 
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Treatment of the 10 patients was limited to the use of oral 
prednisone for symptomatic dermatitis. In addition, expo-
sure to TAe was minimized by reducing the total dose by 
half and by administering the TAe as a single daily dose un-
til 24-h trough levels were at or below 5 ng/mL. With this 
regimen, all skin rashes resolved despite the presence of 
up to 30% donor cells in peripheral blood. None of these 
10 patients developed late rejection. 
Immunosuppression dosing 
First 3 months: At the end of 3 months, the mean trough 
level of the whole group was 10.1 ± 4.2 ng/mL. Thirty-
five of the 36 patients were on TAC: 23 were on twice 
daily doses (trough level 11.5 ± 4.0 ng/mL); 11 were on 
one dose/day (trough 7.68 2.6 ng/mL) and one was on one 
dose every other day (trough 4.1 ng/mL). The 36th recipient 
had been converted to twice daily sirolimus because of 
TAC-associated hemolysis. 
Throughout the 3 months, steroids were temporarily added 
only for treatment of biopsy-proved rejection of either the 
allograft intestine or liver allograft, or because of some 
other immunological event (e.g. GVHD). At the 3 month 
milestone, only six (17%) of the 36 recipients were on pred-
nisone (range 2.5-10 mg/day). However, only 12 (33%) of 
the 36 patients were considered to have reached a stable 
state of minimal monotherapy: 11 on once per day TAC 
doses, and the 12th on an every other day schedule. 
After 3 months: Patients who developed intestinal al-
lograft rejection thereafter had highly individualized treat-
ment, most commonly with prednisone, but in some cases 
with muromonab-CD3 or the brief addition of sirolimus or 
MMF. The ultimate goal was to reach a state of monother-
apy. This was accomplished in 16 of the 34 patients. After 
8-28 months, immunosuppression of the 34 surviving pa-
tients consists of TAC only (n = 14), TAC plus prednisone 
(n = 15), TAC plus sirolimus (n = 2), TAC plus AZA in one 
and TAC plus sirolimus and prednisone in one. The mean 
maintenance prednisone doses in the 15 patients who 
are not steroid free are 0.3 ± 0.22 mg/kg. Those patients 
on TAe monotherapy (n = 14) are receiving it twice daily 
(n = 4), once daily (n = 9) and every other day (n = 1). 
Discussion 
The strategy reported here has been associated with im-
proved patient and graft survival, and effective control of 
rejection, despite minimization of drug treatment during 
the first three postoperative months and subsequently. In 
addition, the incidence of drug toxicity was modest and 
there was a reduction of infections and malignancies. Rel-
ative to our historical experience with infants and children 
(1), the 3% incidence of CMV disease and PTLD has been 
dramatically reduced. The one case of PTLD, however, was 
severe and was refractory to rituximab infusions and radi-
ation/chemotherapy. 
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The nature of ITx has seen a continuous decline in sur-
vival (principally within the first few years). Innovations 
in management strategies have addressed multiple sur-
gical, clinical and immunosuppressive issues in sequen-
tial and at times overlapping periods. Consequently, de-
velopmental strides have been slow and incremental. The 
immunosuppressive strategy reported here incorporates 
an attempt to modify the immunosuppressive load within 
the first post-transplant year, and is measurable by the 
steroid-free rate ana ability to minimize TAe dosing. There-
fore, a rejection free rate of 56% and 45% at 30 and 
90 days, respectively, reflects a significant improvement 
over our previous experience (1). These results must, how-
ever, be taken in light of the 'uncontrolled series' nature of 
the trial. Longer-term results and the possibility of future 
multicenter randomized trials may help to validate these 
initial observations. The incidence of late rejection (after 
90 days) in eight (22%) patients, of which five were first 
time episodes, reflects the stability of this strategy, af-
ter the induction effects of the ATG have subsided. It is 
during this period that acceptance of the allograft under 
lower exposure levels of immunosuppression has occurred 
in over 50% of survivors. The impact of rejection at this 
stage is yet to be determined; however, the more ominous 
spectre of exfoliative on chronic rejection has not been 
seen. 
Use of this protocol has required considerable flexibil-
ity of management. Factors influenCing absorption and 
metabolism are highly variable at di"fferent stages after ITx. 
Consequently, dose adjustments are necessary at different 
stages of convalescence to avoid breakthrough rejection 
at one extreme, or toxic drug levels at the other. Never-
theless, the combination of lymphoid depletion at the out-
set followed by minimal maintenance immunosuppression 
has allowed the elimination of steroids in the majority of 
patients and minimal steroid dependence in most of the 
others. 
Morbidity associated with this protocol included the occur-
rence of renal failure (6%) and hypertension (11 %), which 
reflect a combination of long-term illness, peri-operative 
fluid issues and drug toxicities which includes the use of 
tacrolimus. Since the induction phase TAC dosing parallels 
previous standard guidelines, any changes are expected 
to be modest. However, we are hopeful that the ability to 
minimize TAC dosing with this protocol will provide better 
long-term renal function. Blood-borne infection with bac-
teria and fungi was frequent (61 %). However, this is com-
monly seen after ITx for two principal reasons: the trans-
plantation of a contaminated intestinal graft, and the need 
to maintain venous catheter access for periods of as long 
as 1 year. Consequently, the frequency of such infections 
would be expected to be similar under any protocol; reports 
by other centers have documented infection rates of 90%, 
with a significant mortality rate (21). It is difficult to ascribe 
the frequency observed in this series to the immunosup-
pressive protocol utilized herein; however, the occurrence 
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of only one mortality from catheter associated sepsis is 
encouraging. 
The true measure of the impact of immunosuppressive 
drug therapy remains the frequency and severity of infec-
tion with invasive fungi (not seen in this series) and viruses, 
principally EBV and CMV which occurred with a frequency 
of 33% and 8%, respectively. The majority of cases were 
asymptomatic and detected by routine viral monitoring, 
and were successfully treated preemptively. However, pro-
gression to life-threatening viral disease (PTLD) occurred in 
one patient (3%); this reflects a dramatic decrease from our 
previous experience (1). In an uncontrolled clinical trial, we 
can only speculate that such a beneficial effect may be due 
to this immunosuppressive protocol, i.e. the elimination of 
steroids in 47% of patients, the intent to minimize TAC ex-
posure and a lower incidence of rejection. However, the 
rate of patients at risk (as revealed by a positive EBV-PCR) 
has remained comparatively unchanged (1). Consequently, 
intestinal transplant recipients must still be considered sus-
ceptible to developing EBV-related complications. There-
fore, the beneficial effect of preemptive antiviral therapy 
continues to play an important role with ITx (16). 
'Intestinal failure requires the use of parenteral nutrition as 
long as it persists' (22). Consequently, the standard for suc-
cess after ITx has been freedom from TPN; this has been 
achieved in 95% of the recipients. Of concern, however, 
has been the need for intravenous fluid support, which has 
been required for up to 1 year after ITx, both historically and 
in this report. As with our previous cohorts of patients, the 
need for such support decreases over time (as the enteral 
nutritional intake is optimized). and as the patients progress 
to closure of their intestinal stomas. However, with im-
provements in short- and long-term survival, the 'cure' of 
intestinal failure will have to be measured by a higher stan-
dard which addresses this and other issues such as native 
gut dysmotility, pancreatitis, diabetes mellitus and quality 
of life. Consequently, we maintain cautious optimism, and 
realize that the standards of success must now take into 
account all levels of medical support. These will be criteria 
to assess both historic and future innovations. 
The donor lymphoid population of the intestinal allograft 
and its fate in the recipient after ITx has been a point 
of continuous experimental study and clinical inquiry (23). 
The intestine contains a large and highly mobile lymphoid 
cell population which, after transplantation, are replaced 
by recipient cells. It has been suggested that such im-
munocytes may enhance intestinal allograft immunogenic-
ity/alloreactivity, however, others have theorized such a 
phenomenon may be responsible for varying degrees of 
graft acceptance and even tolerance (24,25). The clinical 
translations of these phenomena have been rejection and 
GVHD. Historical concern about the threat of GVHD after 
ITx (26,27) prompted strategies to deplete the donor im-
munocyte population of the allograft or change its lineage 
composition (20). In clinical experience, however, the In-
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cidence of GVHD has been approximately 5% (28). The 
unexpected low rate may be explained by the reciprocal 
induction of clonal activation -+ exhaustion -+ deletion of 
coexisting immune competent donor and recipient cells 
(29). 
In this context, the acute interaction of the two hema-
tolymphopoietic cell populations is central to alloengraft-
ment. Thus, the frequent presence in these patients of 
enough donor leukocyte chimerism to be detectable by 
flow cytometry, even when associated with clinical mani-
festations of GHVD, was not viewed with panic. The pres-
ence of GVHD was interpreted as achieving a level of 
'chimerism' whereby minimization of TAC could be initi-
ated as part of clinical management. In fact. the symptoms 
usually were readily controlled with steroids and/or by re-
ducing the doses qf baselineTAC immunosuppression. Pa-
tients with GVHR (non-specific signs and symptoms not 
diagnostic of GVHD) responded in a similar fashion. Long-
term follow up of these and the asymptomatic patients (for 
which no chimeric data are available) will be necessary in 
order to assess the significance of persistent donor cells in 
the host. Likewise, allograft rejection, while occurring in up 
to 44% of children within the first month, has usually been 
sensitive to steroids and has not been associated with the 
development of chronic rejection. In fact. chronic intestinal 
allograft rejection has not yet been encountered in any of 
our patients treated with our current protocol. Though the 
significance of stable donor cell chimerism is currently un-
known, we speculate that. in the context of this protocol, 
it may reflect donor-specific hyporesponsiveness; this has 
been reported by others (30). 
Although the follow-up is still short, patient and graft sur-
vival to this point has improved relative to our historical 
experience and to that of multicenter registries. We pos-
tulate that our low, incidence of in~ectious complications is 
primarily due to the reduced cumulative exposure to im-
munosuppression. The low rate of nephrotoxicity, newon-
set diabetes and hypertension also is consistent with this 
hypothesis. 
In conclusion, perioperative lymphoid depletion may allow 
significant successful improvement in survival in children 
who require ITx. Engraftment can be achieved without 
the use of steroids as a maintenance drug in more than 
50% of cases. Long-term follow-up and immune monitor-
ing in these children may lead to further understanding of 
the immunologic events allowing for a minimization strat-
egy. More importantly, however, further experience with 
long-term stability, as well as late and chronic rejection, is 
required. 
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